Product Name
ACSF3, siRNA
Full Product Name
ACSF3 siRNA (Human)
Product Synonym Names
Acyl-CoA synthetase family member 3 mitochondrial
Product Gene Name
ACSF3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q4G176
Specificity
ACSF3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ACSF3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ACSF3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ACSF3 sirna
siRNA to inhibit ACSF3 expression using RNA interference
Applications Tested/Suitable for ACSF3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ACSF3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001120686.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001127214.3
[Other Products]
UniProt Primary Accession #
Q4G176
[Other Products]
UniProt Secondary Accession #
Q6INA0; Q8N2F7; A8K4J8; C9JQL6[Other Products]
UniProt Related Accession #
Q4G176[Other Products]
Molecular Weight
64,130 Da
NCBI Official Full Name
acyl-CoA synthetase family member 3, mitochondrial isoform 1
NCBI Official Synonym Full Names
acyl-CoA synthetase family member 3
NCBI Official Symbol
ACSF3??[Similar Products]
NCBI Protein Information
acyl-CoA synthetase family member 3, mitochondrial
UniProt Protein Name
Acyl-CoA synthetase family member 3, mitochondrial
Protein Family
Acyl-CoA synthetase family
UniProt Gene Name
ACSF3??[Similar Products]
UniProt Entry Name
ACSF3_HUMAN
NCBI Summary for ACSF3
This gene encodes a member of the acyl-CoA synthetase family of enzymes that activate fatty acids by catalyzing the formation of a thioester linkage between fatty acids and coenzyme A. The encoded protein is localized to mitochondria, has high specificity for malonate and methylmalonate and possesses malonyl-CoA synthetase activity. Mutations in this gene are a cause of combined malonic and methylmalonic aciduria. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Sep 2013]
UniProt Comments for ACSF3
ACSF3: Catalyzes the initial reaction in intramitochondrial fatty acid synthesis, by activating malonate and methylmalonate, but not acetate, into their respective CoA thioester. May have some preference toward very-long-chain substrates. Defects in ACSF3 are the cause of combined malonic and methylmalonic aciduria (CMAMMA). A metabolic disease characterized by malonic and methylmalonic aciduria, with urinary excretion of much larger amounts of methylmalonic acid than malonic acid, in the presence of normal malonyl-CoA decarboxylase activity. Clinical features include coma, ketoacidosis, hypoglycemia, failure to thrive, microcephaly, dystonia, axial hypotonia and/or developmental delay, and neurologic manifestations including seizures, psychiatric disease and/or cognitive decline. Belongs to the ATP-dependent AMP-binding enzyme family.
Protein type: EC 6.2.1.-; Ligase; EC 6.-.-.-
Chromosomal Location of Human Ortholog: 16q24.3
Cellular Component: mitochondrion
Molecular Function: acid-thiol ligase activity; ATP binding
Biological Process: fatty acid metabolic process; fatty acid biosynthetic process
Disease: Combined Malonic And Methylmalonic Aciduria
Research Articles on ACSF3
1. ACSF3 was significantly upregulated, and was involved in fatty acid and lipid metabolism and accelerated liver injury in alcoholic liver disease.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
